SCHEMBL4879443

SCHEMBL4879443

O=CNCc1cc(F)cc(C(F)(F)F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.41
ALDH1A1 P00352 1/20 0.41
NTRK1 P04629 2/20 0.40
ADH1B P00325 1/20 0.40
ADH1C P00326 1/20 0.40
ADH1A P07327 1/20 0.40
ADH7 P40394 1/20 0.40
MTOR P42345 2/20 0.40
HTT P42858 1/20 0.39
RHOC P08134 1/20 0.39
RHOA P61586 1/20 0.39
NAMPT P43490 1/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
TACR1 P25103 2/20 0.37
MLYCD O95822 1/20 0.37
VNN1 O95497 2/20 0.36
NTRK3 Q16288 1/20 0.36
NTRK2 Q16620 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5394069 0.98 CYP3A4 (0.40) CYP3A4ALDH1A1NTRK1ADH1BADH1C
SCHEMBL568587 0.89 RHOC (0.46) ADH1BADH1CADH1AADH7MTOR
Hydrochloric Acid SCHEMBL3152128 0.87 RHOC (0.45) ADH1BADH1CADH1AADH7MTOR
Hydrochloric Acid SCHEMBL3143818 0.87 RHOC (0.45) ADH1BADH1CADH1AADH7MTOR
SCHEMBL2674124 0.83 ADH1B (0.50) ALDH1A1NTRK1ADH1BADH1CADH1A
Hydrochloric Acid SCHEMBL6256366 0.81 ADH1B (0.48) ALDH1A1NTRK1ADH1BADH1CADH1A
Fumaric Acid SCHEMBL6016595 0.79 TACR1 (0.46) ALDH1A1ADH1BADH1CADH1AADH7
SCHEMBL1295918 0.78 RXRA (0.41) CYP3A4ALDH1A1NTRK1MTORHTT
SCHEMBL28095788 0.77 CYP3A4 (0.41) CYP3A4ALDH1A1MTORHTTRHOC
SCHEMBL7380097 0.77 RXRA (0.39) CYP3A4ALDH1A1MTORHTTRXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 US disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
US-7214680-B2 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors GLAXO GROUP LIMITED (GB) 2007-05-08 US disclosed
EP-1423117-B1 2-SUBSTITUTED 1-ARYLPIPERAZINES AS TACHYKININ ANTAGONISTS AND/OR SEROTONIN REUPTAKE INHIBITORS GLAXO GROUP LTD (GB) 2005-10-19 EP disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 US disclosed
US-20040242592-A1 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors GLAXO GROUP LIMITED (GB) 2004-12-02 US disclosed
EP-1423117-A1 2-SUBSTITUTED 1-ARYLPIPERAZINES AS TACHYKININ ANTAGONISTS AND/OR SEROTONIN REUPTAKE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-06-02 EP disclosed
WO-2003015784-A1 2-SUBSTITUTED 1-ARYLPIPERAZINES AS TACHYKININ ANTAGONISTS AND/OR SEROTONIN REUPTAKE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES SCN3A, TRPV3, HCN3 CYP3A4 2035/4885ALDH1A1 3589/4885NTRK1 1325/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 CYP3A4 2035/4885ALDH1A1 3589/4885NTRK1 1325/4885
US-20040242592-A1 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors SLC6A4, TPH1, HTR1D CYP3A4 996/4885ALDH1A1 1543/4885NTRK1 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.